TP53 DNA binding domain mutational status and rituximab-based treatment are independent prognostic factors for pediatric Burkitt lymphoma patients stratification
Haematologica. 2024 Feb 22.
doi: 10.3324/haematol.2023.284868.
Online ahead of print.
1 Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova.
2 Istituto di Ricerca Pediatrica Città della Speranza, Padova.
3 Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova.
4 Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona.
5 Paediatric Hematology and Oncology Unit, Ospedale Pediatrico Microcitemico, Cagliari.
6 Department of Hematology-Oncology, Anna Meyer Children's Hospital Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Firenze.
7 Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Clinical Genetics Unit, Department of Women's and Children's Health, University of Padova, Padova.
8 Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy; Paediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padova University and University Hospital, Padova. lara.mussolin@unipd.it.